黄芪甲苷缓解表柔比星相关心脏毒性的动物实验  

AstragalosideⅣalleviates epirubicin-induced cardiotoxicity in rats

作　　者：栾丽娜[1,2] 朱裴钦 何竹 张渊[1] 单君[1] 傅宇[1] 黄燕 江泉[1] LUAN Li-na;ZHU Pei-qin;HE Zhu;ZHANG Yuan;SHAN Jun;FU Yu;HUANG Yan;JIANG Quan(Department of Ultrasonography,Shanghai Pudong New Area People’s Hospital,Shanghai 201299,China;Department of Echocardiography,Shanghai Geriatric Medical Center,Shanghai 201100,China;Health Assessment Division,Shanghai International Travel Medical Center,Shanghai 200335,China)

机构地区：[1]上海市浦东新区人民医院超声科,上海201299 [2]上海市老年医学中心心脏超声诊断科,上海201100 [3]上海国际旅行卫生保健中心健康评估科,上海200335

出　　处：《中国临床医学》2022年第6期1006-1011,共6页Chinese Journal of Clinical Medicine

基　　金：上海市浦东新区卫生健康委员会卫生计生科研面上项目(PW2019A-27)。

摘　　要：目的探讨黄芪甲苷对表柔比星相关心脏毒性的心肌保护作用。方法将24只Sprague-Dauley(SD)大鼠随机分为4组,分别为对照组(空白溶剂+生理盐水)、模型组(空白溶剂+表柔比星)、低剂量黄芪甲苷治疗组(15 mg/kg黄芪甲苷+表柔比星)与高剂量黄芪甲苷治疗组(75 mg/kg黄芪甲苷+表柔比星),每组6只。用药前及用药后2、4、6周对所有大鼠行超声心动图检查,采用两因素重复测量方差分析评估大鼠心脏收缩功能变化,评价指标包括左室射血分数(left ventricular ejection fraction,LVEF)、三尖瓣环收缩期位移(tricuspid annular plane systolic excursion,TAPSE)及右室面积变化分数(fractional area change,FAC)。用药后6周对所有大鼠心脏取材行Masson染色。结果4组大鼠LVEF不存在组间、时间及组间与时间交互效应。4组大鼠TAPSE存在组间与时间交互效应(P=0.011)。随着时间延长,模型组大鼠TAPSE下降幅度较其余各组显著(P<0.05);TAPSE和FAC在4组间差异均有统计学意义(P<0.001)。模型组大鼠TAPSE和FAC在用药后2周开始下降(P<0.05);低剂量黄芪甲苷治疗组FAC在用药后4周开始下降(P<0.05);高剂量黄芪甲苷治疗组FAC在用药后6周开始下降(P<0.05)。Masson染色显示各组大鼠心肌内不同程度胶原纤维沉积,与右室收缩功能受损程度匹配。结论黄芪甲苷可对抗心肌纤维化、缓解表柔比星相关的心脏毒性,高剂量疗效优于低剂量。Objective To explore the cardioprotective effect of AstragalosideⅣon epirubicin-related cardiotoxicity in rats.Methods Twenty-four Sprague-Dauley(SD)rats were randomly divided into four groups(n=6):control group(blank solvent+normal saline),model group(blank solvent+epirubicin),low-dose AstragalosideⅣgroup(15 mg/kg AstragalosideⅣ+epirubicin)and high-dose AstragalosideⅣgroup(75 mg/kg AstragalosideⅣ+epirubicin).All rats were examined by echocardiography before treatment and at 2,4 and 6 weeks after treatment.Left ventricular ejection fraction(LVEF),tricuspid annular plane systolic excursion(TAPSE)and fractional area change(FAC)were recorded and evaluated by two-factor repeated measures analysis of variance.The cardiac tissue slices were collected for Masson staining at 6 week after treatment.Results There was no significant group effect,time effect and interaction effect in LVEF.There was interaction effect in TAPSE(P=0.011).With the extension of time,the decrease of TAPSE in the model group was more significant than that in other groups(P<0.05).TAPSE and FAC were significantly different among the four groups(P<0.001).Compared with the control group,TAPSE and FAC in the model group decreased significantly at 2 week after treatment,and the FAC in the low-dose and high-dose AstragalosideⅣgroup decreased significantly at 4 and 6 week after treatment,respectively.Masson staining showed that different degrees of collagen fiber deposition in the myocardium,matching the right ventricular systolic dysfunction according to echocardiography.Conclusion AstragalosideⅣcan improve epirubicin-induced cardiotoxicity by alleviating myocardial fibrosis,and the effect of the high-dose is better than the low-dose.

关 键 词：黄芪甲苷 心脏毒性 表柔比星 右室收缩功能 

分 类 号：R730.53[医药卫生—肿瘤]